UK Government and Oxford Nanopore to Launch Pandemic Early Warning System
The UK government has announced partnership with life sciences company Oxford Nanopore to develop a real-time surveillance system aimed at …
All Posts
AI Is Key to Democratizing Drug Discovery
The global drug development landscape is bustling, with over 20,000 biotechs competing for investor attention. Now more than ever, having …
Elsevier Supports Pistoia Alliance to Tackle AI Challenges in Drug Discovery
Elsevier has announced its support for the Pistoia Alliance, a non-profit organization dedicated to dismantling systemic barriers to innovation in …
Accenture Invests in 1910 Genetics to Enhance Drug Discovery With AI
Accenture Ventures has invested in 1910 Genetics, a biotechnology firm specializing in AI-driven drug discovery for both small and large …
Evogene Partners with Google Cloud to Build AI Model for Small Molecule Discovery
Computational biology firm Evogene Ltd. has partnered with Google Cloud to develop an advanced AI foundation model for small molecule …
Absci and Twist Bioscience Collaborate to Design a Novel Antibody with Generative AI
Absci Corporation and Twist Bioscience have announced a collaboration to create a novel therapeutic antibody, integrating Absci’s generative AI drug …
Novo Nordisk Foundation Launches Denmark’s First AI Supercomputer to Accelerate Drug Discovery and Innovation
In a major step for Danish research and industry, the Novo Nordisk Foundation has introduced "Gefion," Denmark's first AI supercomputer, …
Quris-AI Acquires Nortis to Enhance Drug Safety with Kidney-on-Chip Tech
Quris-AI, a company dedicated to enhancing drug safety prediction, has announced its acquisition of Kidney-on-Chip pioneer Nortis, also known as …
Medable Launches Clinical Trial Platform on Google Cloud Marketplace, Expands AI Integration
Medable Inc. has launched its Digital and Decentralized Clinical Trial Platform on Google Cloud Marketplace, bringing advanced trial management and …
Key Trends in Aging Research: Where Are We Now?
Over the past decade, aging research has transitioned from foundational biological studies, including a landmark introduction of 9 hallmarks of …
Archon Biosciences Raises $20M to Develop AI-Enhanced "Antibody Cages" for New Therapeutics
Seattle’s Archon Biosciences, co-founded by David Baker, a recent Nobel Prize winner, has raised $20 million in seed funding to …
Gene Therapy: Lexeo Therapeutics’ LX1001 Shows Promise for APOE4-Associated Alzheimer’s Disease
Lexeo Therapeutics recently presented interim findings from its ongoing Phase 1/2 trial of LX1001, a gene therapy targeting Alzheimer’s disease …